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A single course of rituximab does
not abrogate anti-infliximab
antibodies in patients with
rheumatoid arthritis
The development of anti-infliximab antibodies in 8% to 43% of
infliximab-treated patients is associated with decreased effi-
ciency and increased risk of adverse effects.1–3 An intervention
that can diminish anti-infliximab antibody formation is there-
fore warranted. Rituximab, a chimeric monoclonal antibody
that selectively depletes CD20-positive B lymphocytes, could
potentially inhibit the human antibody response against inflix-
imab. Therefore, we assessed the proportion of patients with
rheumatoid arthritis (RA) in which treatment with rituximab
resulted in the depletion of anti-infliximab antibodies.
Consecutive patients with RA with detectable anti-infliximab
antibodies, who were initiated on treatment with either
rituximab or adalimumab, were included in this prospective
controlled cohort study. There were no exclusion criteria other
than the regular contraindications. Baseline assessment included
measurement of disease activity, demographic and clinical data.
Patients received rituximab (261000 mg intravenously, day 0
and 15) or adalimumab at a dosage of 40 mg subcutaneously
every other week. Anti-infliximab antibody measurements
before the first administration of rituximab and after 16 and
24 were compared with patients treated with adalimumab as
control group. Serum anti-infliximab antibody levels were
determined by a previously described radioimmunoassay.3
The baseline characteristics of the included 32 patients (17
rituximab and 15 adalimumab) are depicted in table 1. Although
the baseline anti-infliximab antibody levels tended to be higher
in the adalimumab group (100 (interquartile range (IQR) 28 to
416 AU/ml) compared to the rituximab group (29 (IQR 19 to
127)), this difference did not reach statistical significance
(p = 0.2). A negative trend was found between baseline anti-
infliximab antibody levels and the interval between the last
administration of infliximab and start of the present therapy
(r =20.32, p = 0.07).
Table 1 Baseline characteristics of patients
Rituximab group
(n = 17)
Adalimumab group
(n = 15)
Age (years) 56 (12) 53 (12)
Women (n, %) 8 (47)* 13 (87)*
Disease duration (years) 15.7 (9.1) 15.8 (7.8)
Previous DMARDs (n) 6.5 (2.6)* 3.7 (2.1)*
Previous biologicals (n) 2.5 (0.9)* 1.3 (0.5)*
Rheumatoid factor positive (n, %) 17 (100) 13 (87)
Disease activity (DAS28) at baseline 6.0 (1.6) 5.0 (1.4)
Interval between last infliximab infusion (months) and present therapy
(median (p25–p75))
25 (7.2 to 36)* 5.8 (2.5 to 25)*
Concomitant DMARD at baseline (n, %) 15 (88) 13 (87)
Methotrexate (n, %) 11 (65) 13 (87)
Dose (mg/week) 13.6 (6.3) 16.9 (9.4)
Azathioprine (n, %) 2 (12) 0
Leflunomide (n, %) 1 (6) 0
Oral corticosteroids at baseline (n, %) 10 (59) 5 (33)
Dose (mg/day) 9.3 (2.9)* 4.9 (1.9)*
Variables are expressed as mean (SD) unless stated otherwise.
*p,0.05.
DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug.
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After 24 weeks, the median serum anti-infliximab antibody
levels in the rituximab group and adalimumab group decreased
from 29 AU/ml to 23 AU/ml and from 100 AU/ml to 44 AU/ml,
respectively (fig 1). The mean (SD) decrease in anti-infliximab
antibody levels was not more pronounced in the rituximab group
(20% (38%) reduction) compared to the adalimumab group (36%
(52%) reduction). Rituximab treatment did not lead to serocon-
version of anti-infliximab antibodies in any of the patients. One
adalimumab-treated patient had anti-infliximab levels below the
cut-off level of 12 AU/ml. A linear regression association model
showed that baseline anti-infliximab antibody levels did not act as
a confounder on the relation between decrease in anti-infliximab
antibodies and received treatment.
The results presented here show that rituximab neither
abrogates anti-infliximab antibodies nor modulates the change
of existing anti-infliximab antibody levels compared to adali-
mumab. Non-selective inclusion, broad inclusion criteria,
blinded assessment of anti-infliximab antibody levels, the use
of a comparable control group and the application of linear
regression to detect possible confounders, all supported an
adequate internal validity of the study. Although our data show
that anti-infliximab antibody levels do not seem to be affected
by rituximab, this does not necessarily imply that rituximab
will not affect the production of anti-infliximab antibodies in
the presence of infliximab. Conceivably, reintroduction of
infliximab in patients with anti-infliximab antibodies pre-
viously treated with rituximab could lead to decreased forma-
tion of anti-infliximab antibodies by short-lived plasma cells.
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High-resolution MRI for assessment
of middle meningeal artery
involvement in giant cell arteritis
Giant cell arteritis (GCA) typically involves the superficial
cranial arteries, the aorta and its branches. It has been discussed
to which extent the vasculitic changes of the cranial arteries
continue into the intracranial region. Autopsy findings have
indicated that the characteristic signs of arteritic inflammation
of GCA end after crossing the dural border.1 In a recent review
of several published cases it was concluded that intracranial/
intradural involvement in GCA is rare and represents a small
subset of GCA that is non-responsive to corticosteroids and has
a fatal course.2
Contrast-enhanced, high-resolution MRI allows non-invasive
assessment of mural inflammation in the extracranial, superficial
arteries in giant cell arteritis.3 Here, we report MRI findings
suggestive of intracranial vasculitic involvement in patients
with GCA. High-resolution MRI of 50 patients with GCA
(15 men, 35 women, mean age 70.4 years) and signs of cranial
arteritis in MRI scans acquired at 1.5 and 3 Tesla were
retrospectively evaluated by 2 radiologists. Imaging para-
meters of the applied contrast enhanced, fat saturated
multislice T1-weighted spin echo (SE) sequence have been
reported elsewhere.4 5
Utilising the above-mentioned MRI protocol, mural thicken-
ing and contrast enhancement of the intracranial but extradural
course of the medial meningeal artery (MMA), most likely
representing mural inflammatory changes, was depicted in 16
patients (32%) (fig 1). These findings were bilateral in nine
patients and unilateral in seven patients.
In 32 patients the diagnosis of GCA was established by
positive temporal artery biopsy (TAB). In 6 of the other 18
patients TAB was negative. In these cases, as well as in the 12
cases in which no TAB was performed, GCA was established
Figure 1 Anti-infliximab antibody levels (AU/ml) prior to treatment with
rituximab or adalimumab (t = 0) and 16 and 24 weeks after treatment.
Letters
Ann Rheum Dis August 2009 Vol 68 No 8 1369
 group.bmj.com on August 15, 2011 - Published by ard.bmj.comDownloaded from 
doi: 10.1136/ard.2008.095448
 2009 68: 1368-1369Ann Rheum Dis
 
B J F van den Bemt, K Vos, A A den Broeder, et al.
 
patients with rheumatoid arthritis
abrogate anti-infliximab antibodies in 
A single course of rituximab does not
 http://ard.bmj.com/content/68/8/1368.full.html
Updated information and services can be found at: 
These include:
References
 http://ard.bmj.com/content/68/8/1368.full.html#ref-list-1
This article cites 3 articles
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on August 15, 2011 - Published by ard.bmj.comDownloaded from 
